Enter Symbol:

Stock Detail

CHINA MEDICAL TECHNOLOGIES INC - AMERICAN DEPOSITARY SHARES EACH REPRESENTING 10 ORDINARY SHARES

China Stocks

CMED @ Yahoo Finance | CMED Option @ Yahoo Finance

Last Day's Data

Current Price High Value Change Percent Change Dividend Previous Close
$4.00 $4.39 $-0.39 -8.88% 0.00 $4.39
Opening Price Low Volume Market Cap Average Volume P/E
$4.37 $3.97 340,888 129.07M 263,304 8.10

Pivot Table

R2 R1 Pivot S1 S2
4.54 4.27 4.12 3.85 3.70

stock chart

Stock Profile

China Medical Technologies, Inc. develops, manufactures, and markets medical devices for the treatment of solid cancers and benign tumors in the People's Republic of China. It offers In-vitro diagnostics systems, which include enhanced chemiluminescence immunoassay (ECLIA) system and fluorescent in situ hybridization (FISH) imaging analysis system and probes. The company's ECLIA system consists of ECLIA analyzer for detecting minute levels of light triggered by combining reagents with body fluid samples to produce diagnostic results; reagent kits, which are formulated to create various reactions with blood or other body fluid samples; and a data analysis system to analyze and organize the information produced form diagnostic results. It offers 62 types of reagent kits for use with the ECLIA analyzer for detecting and monitoring various types of diseases and disorders, including thyroid disorders, diabetes, hepatitis, and disorders related to reproduction and growth, SARS, Down syndrome, liver fibrosis, and various types of tumors. China Medical Technologies also offers FISH imaging analysis system and probes, which uses FISH technology for prenatal and postnatal diagnosis, and early detection and prognosis of various cancers. In addition, the company provides HIFU therapy system to treat liver, breast, and kidney tumors; solid tumors in the pelvic cavity or on bone; and tumors in the four limbs or superficial tissues. It sells its products through direct sales force and distributors. China Medical Technologies was founded in 1999 and is based in Beijing, the People's Republic of China.